Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

NCT03771820 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

SCCHN

Interventions

DRUG: NC-6004
DRUG: Pembrolizumab

Sponsor

NanoCarrier Co., Ltd.

Collaborators

[object Object]